InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.089

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$27 FNN Interview with Graham on recent LuPIN interim data 2 Oct 2019 9:36AM $0.405 $0.089 fallen by 78.02%
$27 Further Review Shows Major Clinical Benefits from Veyonda 30 Sep 2019 10:20AM $0.360 $0.089 fallen by 75.28%
$27 Annual Report to Shareholders 26 Sep 2019 10:17AM $0.385 $0.089 fallen by 76.88%
$27 Appendix 4G 26 Sep 2019 10:10AM $0.385 $0.089 fallen by 76.88%
$27 Corporate Governance Statement 26 Sep 2019 10:08AM $0.385 $0.089 fallen by 76.88%
$27 Section 708 Certificate 26 Sep 2019 10:07AM $0.385 $0.089 fallen by 76.88%
$27 Section 708 Certificate 26 Sep 2019 10:05AM $0.385 $0.089 fallen by 76.88%
$27 Appendix 3B 26 Sep 2019 10:04AM $0.385 $0.089 fallen by 76.88%
$27 Amended/Departure of Dr Van Wyk 24 Sep 2019 2:30PM $0.380 $0.089 fallen by 76.58%
$27 Departure of Dr Wan Wyk 24 Sep 2019 2:15PM $0.380 $0.089 fallen by 76.58%
$27 Veyonda and Radiotherapy Profiled at Key Oncology Meeting 17 Sep 2019 1:08PM $0.375 $0.089 fallen by 76.27%
$27 Results of Meeting 16 Sep 2019 12:32PM $0.395 $0.089 fallen by 77.47%
$27 NOX EGM Chairman's Address and Presentation 16 Sep 2019 9:11AM $0.360 $0.089 fallen by 75.28%
$27 CHANGE OF DIRECTOR'S INTEREST NOTICE - GK 12 Sep 2019 12:20PM $0.365 $0.089 fallen by 75.62%
$27 CHANGE OF DIRECTOR'S INTEREST NOTICE - GK 10 Sep 2019 10:47AM $0.355 $0.089 fallen by 74.93%
$27 Appendix 4E and Audited Financial Statements FY19 29 Aug 2019 7:13PM $0.355 $0.089 fallen by 74.93%
$27 Addendum to Notice of Extraordinary General Meeting 28 Aug 2019 7:14PM $0.390 $0.089 fallen by 77.18%
$27 More Evidence that Veyonda Enhances RT in Prostate Cancer 28 Aug 2019 9:26AM $0.455 $0.089 fallen by 80.44%
$27 NOX Receives FY19 Federal Government R&D Tax Rebate 23 Aug 2019 3:13PM $0.410 $0.089 fallen by 78.29%
$27 Appendix 3B 23 Aug 2019 3:06PM $0.410 $0.089 fallen by 78.29%
$27 Cleansing Statement 23 Aug 2019 3:05PM $0.410 $0.089 fallen by 78.29%
$27 Pre-Clinical Evidence Confirms Veyonda Abscopal Effect 21 Aug 2019 10:55AM $0.390 $0.089 fallen by 77.18%
$27 Lead Manager Appointed for Proposed Nyrada IPO 15 Aug 2019 8:19AM $0.400 $0.089 fallen by 77.75%
$27 Notice of Extraordinary General Meeting/Proxy Form 12 Aug 2019 8:46AM $0.435 $0.089 fallen by 79.54%
$27 Noxopharm Corporate Update Interview 9 Aug 2019 11:11AM $0.435 $0.089 fallen by 79.54%

501 - 525 of 797 results

Page 21 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.